Home
>
National Drug Code (NDC)
>
CRIXIVAN
CRIXIVAN - 0006-0571-43 - (indinavir sulfate)
Drug Information of CRIXIVAN
| Product NDC: | 0006-0571 |
| Proprietary Name: | CRIXIVAN |
| Non Proprietary Name: | indinavir sulfate |
| Active Ingredient(s): | 200 mg/1 & nbsp; indinavir sulfate |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of CRIXIVAN
| Product NDC: | 0006-0571 |
| Labeler Name: | Merck Sharp & Dohme Corp. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA020685 |
| Marketing Category: | NDA |
| Start Marketing Date: | 19960313 |
Package Information of CRIXIVAN
| Package NDC: | 0006-0571-43 |
| Package Description: | 360 CAPSULE in 1 BOTTLE (0006-0571-43) |
NDC Information of CRIXIVAN
| NDC Code | 0006-0571-43 |
| Proprietary Name | CRIXIVAN |
| Package Description | 360 CAPSULE in 1 BOTTLE (0006-0571-43) |
| Product NDC | 0006-0571 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | indinavir sulfate |
| Dosage Form Name | CAPSULE |
| Route Name | ORAL |
| Start Marketing Date | 19960313 |
| Marketing Category Name | NDA |
| Labeler Name | Merck Sharp & Dohme Corp. |
| Substance Name | INDINAVIR SULFATE |
| Strength Number | 200 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | HIV Protease Inhibitors [MoA],Protease Inhibitor [EPC] |
